Medtronic Unveils Three-Year SPYRAL HTN-ON MED Trial Results on Renal Denervation Efficacy
Reuters
Oct 23
Medtronic Unveils Three-Year SPYRAL HTN-ON MED Trial Results on Renal Denervation Efficacy
Medtronic plc has announced new clinical milestones spanning its coronary, renal denervation, and structural heart businesses, with several key data presentations scheduled for the upcoming 37th Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. The company will present new evidence on the real-world usage of the Prevail™ Drug-Coated Balloon in complex coronary artery lesion populations, including diabetic patients. Additionally, final global results from the Optimize PRO Study, involving 653 patients across 50 centers, will highlight outcomes in transcatheter aortic valve replacement procedures. In the renal denervation segment, Medtronic will report final three-year results from the SPYRAL HTN-ON MED randomized study, assessing the durability of blood pressure reductions using the Symplicity Spyral™ renal denervation system in patients on antihypertensive medications. The first results from the SPYRAL AFFIRM study will also be presented, evaluating the impact of renal denervation on blood pressure in a large cohort of high cardiovascular risk patients in the US. These results are scheduled to be presented during the TCT symposium.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on October 23, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.